Effects of dietary nitrate supplementation on the response to extremity cooling and endothelial function in individuals with cold sensitivity. A double blind, placebo controlled, crossover, randomised control trial by Clare Eglin (7152989) et al.
1 
 
Effects of dietary nitrate supplementation on the response to extremity cooling and 1 
endothelial function in individuals with cold sensitivity. A double blind, placebo 2 
controlled, crossover, randomised control trial. 3 
 4 
Clare M Eglin1, Joseph T Costello1, Stephen J Bailey2, Mark Gilchrist3, Heather Massey1, 5 
Anthony I Shepherd1 6 
 7 
1Department of Sport and Exercise Science, University of Portsmouth, UK, 8 
 2School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK, 9 
3University of Exeter Medical School and NIHR Exeter Clinical Research Facility, Royal Devon 10 
and Exeter Hospital, Exeter, Devon, UK. 11 
 12 
Corresponding author: 13 
Dr Anthony Shepherd 14 
Department of Sport and Exercise Science 15 
Spinnaker Building 16 
Cambridge Road 17 
Portsmouth, UK 18 
PO1 2ER 19 
Email address –ant.shepherd@port.ac.uk 20 
Key words: 21 
Nitrate  22 
Nitric oxide 23 
Microvascular  24 
Beetroot 25 
Non-freezing cold injury 26 
 27 
 28 
2 
 
Abbreviations 29 
ACh acetylcholine 30 
CVC cutaneous vascular conductance 31 
MAP mean arterial pressure 32 
NFCI non-freezing cold injury  33 
NO• nitric oxide 34 
RSNO S-Nitrosothiols  35 
eNOS endothelial nitric oxide synthase  36 
 37 
Word count  38 
Abstract: 261 39 
Manuscript:  40 
 41 
Abstract  42 
Individuals with cold sensitivity have low peripheral skin blood flow and skin temperature 43 
possibly due to reduced nitric oxide (NO•) bioavailability. Beetroot has a high concentration 44 
of inorganic nitrate and may increase NO-mediated vasodilation. Using a placebo-controlled, 45 
double blind, randomised, crossover design, this study tested the hypotheses that acute 46 
beetroot supplementation would increase the rate of cutaneous rewarming following a local 47 
cold challenge and augment endothelium-dependent vasodilation in cold sensitive 48 
individuals.  49 
Thirteen cold sensitive participants completed foot and hand cooling (separately, in 15 °C 50 
water for 2 minutes) with spontaneous rewarming in 30°C air whilst skin temperature and 51 
cutaneous vascular conductance (CVC) were measured (Baseline). On two further separate 52 
visits, participants consumed 140 ml of either concentrated beetroot juice (nitrate 53 
supplementation) or nitrate-depleted beetroot juice (Placebo) 90 minutes before resting 54 
seated blood pressure was measured. Endothelial function was assessed by measuring CVC 55 
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at the forearm, finger and foot during iontophoresis of 1% w/v acetylcholine followed by 56 
foot and hand cooling as for Baseline. 57 
Plasma nitrite concentrations significantly increased in nitrate supplementation compared 58 
to Placebo and Baseline (502 ± 246 nmol.L-1; 73 ± 45 nmol.L-1; 74 ± 49 nmol.L-1 respectively; 59 
n=11; P < 0.001). Resting blood pressure and the response to foot and hand cooling did not 60 
differ between conditions (all P > 0.05). Nitrate supplementation did not alter endothelial 61 
function in the forearm, finger or foot (all P > 0.05) compared to Placebo.  62 
Despite a physiologically meaningful rise in plasma nitrite concentrations, acute nitrate 63 
supplementation does not alter extremity rewarming, endothelial function or blood 64 
pressure in individuals with cold sensitivity. 65 
 66 
1.0 Introduction 67 
Non-freezing cold injury (NFCI) is caused by prolonged exposure to cold, and often cold and 68 
wet, conditions. NFCI most commonly affects the feet, although the hands can also be 69 
affected (Eglin et al. 2013). Chronic NFCI, which may last for many years, is characterised (in 70 
variable combination and severity) by cold sensitivity, numbness, hyperhidrosis and 71 
persistent pain which can significantly affect an individual’s quality of life (Golden et al. 72 
2013). NFCI has been reported in individuals following exposure to cold environments such 73 
as: mountaineering and hill walking (Imray et al., 2009), diving (Laden et al., 2007), cycling 74 
(Fraser and Loftus, 1979), in homeless individuals (Wrenn, 1991) and the elderly (Williams et 75 
al., 2005) as well as in individuals working in cold environments, (Mills and Mills, 1993, 76 
Cattermole, 1999, Golden et al., 2013).   77 
Although severe NFCI can be debilitating, its pathophysiology is not fully understood and 78 
therefore a definitive diagnostic tool is not available (Eglin et al., 2013). Sub-clinical forms of 79 
NFCI have also been characterised in individuals frequently exposed to cold conditions for 80 
short durations during recreational activities such as windsurfing, surfing and open water 81 
swimming. These individuals are cold sensitive (their hands and feet are cooler than 82 
“normal” individuals and they take longer to rewarm following cold exposure) but are not 83 
considered to have a cold injury (Eglin, 2011). As with NFCI and primary Raynaud’s 84 
(Gardner–medwin et al., 2001, O'Reilly et al., 1992), this cold sensitivity is associated with a 85 
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reduced basal skin blood flow and a smaller increase in skin blood flow upon rewarming 86 
(Davey et al., 2013, Hope et al., 2014). The resultant cooler peripheral skin temperature will 87 
result in reduced skin oxygen tension (Sheffield et al., 1996, Montgomery and Horwitz, 88 
1950) and may put these individuals at greater risk of cold injury on subsequent cold 89 
exposure (Cattermole, 1999).  90 
Animal models of NFCI have shown reduced levels of oxygen in the cooled tissues 91 
(Montgomery et al., 1954) and that NFCI may be associated with a pro oxidant state (Geng 92 
et al., 2015). Local cooling has been shown to inhibit endothelial nitric oxide synthase 93 
(eNOS) as well as increase noradrenaline release (Hodges et al., 2006). In addition, eNOS 94 
activity has been shown to be positively associated with temperature (Kellogg et al., 2008). 95 
Nitric oxide (NO•) is a known vasodilator and plays a fundamental role in the control of skin 96 
blood flow (Hodges et al., 2006, Minson et al., 2001). Moreover, NO• released from S-97 
nitrosohemoglobin (Stamler et al., 1997) in hypoxic environments plays a key role in 98 
regulating the physiological oxygen gradient. We have previously shown that glyceryl 99 
trinitrate, a NO• donor, increases the rate of rewarming following foot cooling in individuals 100 
with cold sensitivity (Hope et al., 2014). However, individuals develop a tolerance to GTN 101 
and show diminishing vasodilatory effects with chronic treatment (Needleman and Johnson, 102 
1973). In addition, the deleterious side effects such as headaches (Hsi et al., 2005) suggests 103 
that organic nitrates are not optimal long-term therapies for individuals with cold sensitivity.   104 
Leafy green vegetables and particularly beetroot have a high concentration of inorganic 105 
nitrate (Bryan and Hord, 2010). These vegetables are thought to be beneficial to 106 
cardiovascular health due to their vasodilatory effects (Gilchrist et al., 2010) with recent 107 
reports suggesting that tolerance to inorganic nitrate does not occur (as inferred by blood 108 
pressure responses) for at least 28 days (Thompson et al., 2017). Inorganic nitrate can act as 109 
a source of systemic NO• generation (Lundberg and Govoni, 2004). Briefly, inorganic nitrate 110 
is converted to nitrite by facultative anaerobic bacteria on the dorsum of the tongue 111 
(Duncan et al., 1995) with small quantities of this nitrite being converted to NO• and other 112 
nitrogen oxides such as S-Nitrosothiols (RSNO) by the acidic environment of the stomach 113 
(Benjamin et al., 1994). The remaining nitrite and RSNO are then absorbed into the 114 
circulation where they act as a storage pool for subsequent NO• production (Lundberg and 115 
Weitzberg, 2005), which is expedited in hypoxaemia (Cosby et al., 2003), such as that 116 
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observed in cold sensitivity (Davey et al., 2013, Montgomery and Horwitz, 1950, Sheffield et 117 
al., 1996, Hope et al., 2014). This enterosalivary pathway and its purported therapeutic 118 
effects have been reviewed elsewhere (Lundberg et al., 2008). Inorganic nitrate, in the form 119 
of beetroot juice, improves skin blood flow (Levitt et al., 2015), microvascular function (Keen 120 
et al., 2014) and lowers blood pressure (BP) in healthy individuals (Webb et al., 2008) and in 121 
individuals with hypertension (Kapil et al., 2015) and peripheral arterial disease (Kenjale et 122 
al., 2011). In contrast, some studies have shown no effect of nitrate supplementation on 123 
vascular health markers despite increases in circulating NO• intermediates in healthy (Bahra 124 
et al., 2012, Shepherd et al., 2016) and clinical populations (Gilchrist et al., 2013). However, 125 
the potential for beetroot juice to offer an inexpensive, safe and potentially effective 126 
intervention to improve peripheral circulation in individuals with cold sensitivity has not 127 
been studied. Recently, nitrate supplementation has also been shown to lower sympathetic 128 
nerve activity (Notay et al., 2017)  and nitrate/nitrite has been shown to restore vascular 129 
function when NOS is inhibited (Ferguson et al., 2016, Carlström et al., 2010). Therefore, as 130 
cold sensitive individuals exhibit impaired vascular function possibly due to lower eNOS 131 
activity and increased sympathetic drive, nitrate supplementation, and the associated 132 
increase in the circulating NO• pool, might help alleviate the associated detrimental effects 133 
as shown with organic nitrates (Hope et al., 2014, Anderson et al., 2002).  134 
We hypothesised that compared to baseline and placebo, nitrate supplementation would 135 
increase plasma nitrite concentration, the rate of cutaneous rewarming following a local 136 
cold challenge and augment endothelium-dependant vasodilation in individuals with cold 137 
sensitivity. 138 
 139 
2.0 Methods  140 
All procedures for this randomised placebo-controlled, double-blind, cross-over designed 141 
trial were approved by the University of Portsmouth Science Faculty Research Ethics 142 
committee (2016-107A) and all volunteers provided written informed consent prior to 143 
participation. All testing took place at the Department of Sport and Exercise Science, 144 
University of Portsmouth between January and March 2017 when the outdoor air 145 
temperature averaged 5.8 ± 2.9°C at the time of testing (range 0°C to 10°C). 146 
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2.1 Participants 147 
Participants were recruited based on their self-reported frequent exposure to cold 148 
environments (e.g. winter sea swimming, sailing etc.) or often having cold hands and feet. A 149 
baseline cold sensitivity test (described below) was conducted to determine whether the 150 
participants had cold sensitive feet or hands. This was defined as a toe or finger skin 151 
temperature less than 32°C prior to the cold water immersion and after 5 minutes of 152 
rewarming in 30°C air (House et al., 2015, Eglin et al., 2013). Exclusion criteria included; 153 
diagnosis of a prior freezing injury, peripheral vascular disease, thalassaemias affecting 154 
haemoglobin and / or hepatitis B.  155 
All participants were non-smokers (for at least 1 year). Participants refrained from 156 
consuming food high in nitrate the day before testing and were asked to keep a food diary 157 
for the 24 hours before their first visit to the laboratory and to replicate this prior to each 158 
visit. Participants abstained from alcohol for 24 hours and caffeine for 3 hours prior to 159 
testing. The participants also refrained from using any antibacterial mouth wash for 7 days 160 
prior to each test as this has been shown to reduce the concentration of oral bacterial that 161 
are responsible for the reduction of nitrate to nitrite (Govoni et al., 2008). Female 162 
volunteers were asked about their menstrual cycle to determine whether they were in the 163 
follicular or luteal phase or whether they were peri- or post-menopausal. However, the 164 
phase of the menstrual cycle was not controlled for since reproductive hormone status does 165 
not affect the responses to local cooling (Lunt and Tipton, 2014), thermal perception (Lunt 166 
and Tipton, 2014) or iontophoresis of acetylcholine (Ketel et al., 2009). 167 
2.2 Protocol 168 
The participants attended the laboratory on three separate occasions at the same time of 169 
day to reduce any circadian effects. On arrival at the laboratory, resting seated blood 170 
pressure was measured using an automated blood pressure monitor (Omron HEM-705C, 171 
Omron, Milton Keynes, UK) with the average of the final three measurements from the 172 
brachial artery being recorded and used to calculate mean arterial pressure (MAP). On the 173 
first visit (Baseline) the participants then undertook a cold sensitivity test (see below) and if 174 
they were classified as cold sensitive, a venous blood sample was taken for measurement of 175 
7 
 
plasma nitrate and nitrite using the ozone chemiluminescence technique (Sievers NOA 280; 176 
Analytix Ltd, Durham, UK) using a protocol adapted from Bateman et al. (2002). 177 
One and a half hours before arriving at the laboratory for the second and third visit, which 178 
were separated by a wash-out period of at least 7 days, the participants consumed either 179 
140 ml of concentrated beetroot juice (nitrate supplementation; 11.9 mmol nitrate; Beet it, 180 
James White Drinks Ltd., Ashbocking, UK) or nitrate-depleted concentrated beetroot juice as 181 
a placebo (Placebo; 0.02 mmol nitrate; Beet it, James White Drinks Ltd., Ashbocking, UK). 182 
This dose has been used in previous studies (Shepherd et al., 2016) and results in peak 183 
nitrite concentrations between two and three hours (Wylie et al., 2013) coinciding with the 184 
testing. The placebo was similar to the nitrate-rich beetroot juice in taste, colour, texture, 185 
appearance, odour and packaging (Gilchrist et al., 2014). On arrival at the laboratory the 186 
participants’ blood pressure was measured, as described above, and a venous blood sample 187 
was taken for measurement of plasma nitrate and nitrite. Following this, participants 188 
undertook an endothelium function test followed by a cold sensitivity test of their foot and 189 
hand (both described below).  190 
2.3 Cold sensitivity test 191 
The cold sensitivity test used in this study has been described in detail elsewhere (Eglin et 192 
al., 2013, Hope et al., 2014). Participants entered a climatic chamber controlled at an air 193 
temperature of 30.3 (0.4) °C, removed their shoes and socks, and rested in a semi- 194 
recumbent position for 15 minutes. They then exercised on a cycle ergometer (874E, 195 
Monark, Sweden) for 12 minutes at an external work rate of 50 W (previously shown to 196 
improve the reliability of the test, (Eglin et al., 2013). Following the 12 minutes cycling, the 197 
participant then rested in a semi-recumbent position for 5 minutes whilst resting toe skin 198 
temperature and blood flow were recorded. 199 
The participant’s left foot was then placed in a plastic bag and immersed in a water bath 200 
stirred and maintained at 15.1 ± 0.2 °C to the point of their mid-malleoli for 2 minutes.  201 
After the immersion period, the plastic bag was removed and rewarming monitored for 10 202 
minutes whilst the participant remained resting in a semi-recumbent position.  203 
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The participant then rested in a seated position for 5 minutes whilst finger skin temperature 204 
and blood flow was recorded. The participant, still seated, placed their left hand in a plastic 205 
bag and immersed it to the level of the wrist in water at 15.0 ± 0.2 °C for 2 minutes. After 206 
the immersion period, the plastic bag was removed and rewarming monitored for 10 207 
minutes whilst the participant remained resting in a seated position with their arm 208 
supported by an arm rest.   209 
2.3.1 Measurements 210 
Skin blood flow was measured using a laser Doppler probe (VP1T / 7, Moor Instruments, UK) 211 
placed on the Great toe pads during foot immersion and on the pads of the thumbs during 212 
hand immersion. Skin blood flow was analysed using minute averages before, during and 213 
after immersion (rewarm period) and expressed as cutaneous vascular conductance (CVC = 214 
skin flux/MAP; flux.mmHg-1). CVC was analysed between conditions at the following time 215 
points: pre immersion, 5 and 10 min of rewarming. 216 
Skin temperature was measured using an infrared camera (A320G, FLIR systems, UK) 217 
according to the guidelines described in (Moreira et al., 2017). The camera was positioned 218 
1.0 m away from the sole of the foot and 0.7 m away from the palm of the hand and 219 
recorded using the spot analysis function on the FLIR software (FLIR systems, UK) prior to 220 
immersion and every minute during the 10 minute rewarming periods. Great toe, coldest 221 
toe, mean toe, thumb and mean finger skin temperature were analysed between conditions 222 
at the following time points: pre immersion, 5 and 10 min of rewarming. The coefficient of 223 
variation in our laboratory for the cold sensitivity test is 2.7% for the finger skin 224 
temperatures and 8.7% for the toe skin temperatures (unpublished data, n=13).  225 
Blood pressure was measured on the right arm prior to foot and hand immersion and at the 226 
end of both rewarming periods using an automated blood pressure monitor (Omron HEM-227 
705C, Omron, Milton Keynes, UK) for calculation of MAP.  228 
Thermal sensation and comfort were measured using 20 cm scales (0 = very 229 
cold/uncomfortable; 10 = neutral; 20 = very hot/comfortable; modified from Zhang et al. 230 
(2004)) and recorded prior to immersion, during immersion and every 2 minutes of the 231 
rewarming period. Pain sensation was recorded using a subjective numerical rating scale 232 
9 
 
(NRS) for pain (0 no pain, 10 unimaginable, unspeakable pain; (Ferreira-Valente et al., 2011)) 233 
at the same time points.  234 
2.4 Endothelium function test 235 
Following an acclimation period of at least 20 minutes, acetylcholine (ACh) was delivered 236 
transdermally using iontophoresis to three sites in the following order: volar aspect of the 237 
left forearm, middle phalanx of the middle finger of the left hand and dorsal aspect of the 238 
left foot as previously described (Maley et al. 2017). Briefly, a perspex ring containing the 239 
anode was attached to the skin site with the cathode attached using a gel pad at the wrist or 240 
ankle. Both electrodes were connected to a battery powered iontophoresis controller (MIC 241 
2, Moor Instruments, UK). The anode chamber (8 mm inner diameter) was filled with 242 
approximately 0.5 mL of ACh. ACh was dissolved into sterile water for injection (Braun, 243 
Melsungen, Germany) to yield a concentration of 1%. The protocol consisted of eight pulses: 244 
four pulses of 25 μA followed by a single pulse of 50 μA, 100 μA, 150 µA and a final pulse of 245 
200 µA applied for 20 seconds with 60 second intervals between each pulse where no 246 
current was applied. After an interval of 5 minutes the protocol was repeated on the next 247 
skin site. The tests were conducted at a room temperature of 23.2 (0.4) °C. 248 
2.4.1 Measurements 249 
Skin blood flow was measured using a laser Doppler probe (VP1T / 7, Moor Instruments, UK) 250 
connected to a laser Doppler perfusion monitor (moor VMS-LDF, Moor Instruments, UK). 251 
Flux data from the laser Doppler and iontophoresis controller was recorded using a data 252 
acquisition system and software (Powerlab and LabChart 7, AD Instruments, Australia). The 253 
laser Doppler probe was placed into the perspex ring used for iontophoresis on the forearm, 254 
finger, dorsal foot and on the corresponding site on the contra-lateral limb. Skin blood flow 255 
responses were expressed as CVC.  256 
Average skin blood flow in response to iontophoresis of ACh was calculated over the final 20 257 
seconds of the interval between successive pulses and between 40 to 60 seconds after the 258 
final pulse (Maley et al., 2017). These responses were expressed as absolute CVC as baseline 259 
CVC did not differ between conditions for any site. ED50, expressed as 95 % confidence 260 
intervals, was calculated using GraphPad (Version 5, USA). Maximum skin blood flow and 261 
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area under the curve (AUC) were calculated for each participant. The point at which the skin 262 
blood flow was at a maximum point was not always identified following the final pulse 263 
therefore maximum skin blood flow was taken from wherever it was highest. Skin 264 
temperature was measured adjacent to the iontophoresis site using a skin thermistor 265 
(Grants Instruments, Cambridge) and recorded on a data logger (Grants Instruments, 266 
Cambridge). Blood pressure was measured on the contralateral arm to iontophoresis using 267 
an automated blood pressure monitor (Omron HEM-705C, Omron, Milton Keynes, UK) 268 
before and after each ACh dose response curve for calculation of MAP.  269 
2.5 Sample size and randomisation 270 
An a priori sample size calculation was performed based on data from our previous study on 271 
the effect of GTN in cold sensitive individuals (Hope et al. 2013) which showed a 4.2 ± 3.0 °C 272 
change in skin temperature 10 minutes post immersion during the cold sensitivity test. For 273 
90% power and an α-level of 5% (two tailed) it was calculated that 13 participants were 274 
required.  275 
A computer programme generated a random sequence that was used to assign each 276 
participant to begin the trial in one of two arms. Participants were then supplied with the 277 
requisite juice (in a sealed, opaque envelope prepared by individuals not involved in the 278 
trial) which was counter-balanced and blinded from the participants and researchers.  279 
2.6 Data analysis  280 
As with other studies using this technique (Maley et al., 2017) some individuals had high 281 
skin resistance which meant that it was not possible to deliver all of the current pulses in 282 
each skin site for all participants. Therefore, only those who were able to receive the first 283 
pulse of iontophoresis were included in analyses. Where an incomplete current response 284 
curve was delivered (due to high skin resistance at the higher currents), the number of 285 
pulses used in the analysis was the same within individual for both conditions. A blood 286 
sample was not obtained from two participants due to technical difficulties and therefore 287 
n=11 for Baseline and n=12 for Placebo and nitrate supplementation for plasma nitrate and 288 
nitrite concentrations.  289 
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 Assumption of normal distribution of data was assessed using descriptive methods 290 
(skewness, outliers, and distribution plots) and inferential statistics (Shapiro–Wilk test). 291 
Where normality was not met, nonparametric tests were performed. For the cold sensitivity 292 
test, statistical differences were assessed using repeated measures ANOVAs (condition 293 
[Baseline, Placebo, nitrate supplementation] * time [pre immersion, 5 min, 10 min]) for toe 294 
skin temperatures, thumb and Great toe skin blood flows. Finger skin temperatures, thermal 295 
comfort, thermal sensation and pain were analysed using Friedman tests. For the 296 
endothelial function test, maximum CVC, AUC and skin temperature were analysed using 297 
ANOVAs (condition [Baseline, Placebo, nitrate supplementation] * skin site [forearm, finger, 298 
foot]). ED50 values were analysed using paired samples t-test.  Plasma nitrate and nitrite 299 
concentrations were analysed using a one way ANOVA. Where appropriate, post-hoc tests 300 
were conducted using pairwise comparisons with Bonferroni corrections. Data are 301 
presented as mean (SD), unless otherwise stated. Statistical analysis was performed on SPSS 302 
version 22 (Chicago, IL) and statistical difference was accepted as P < 0.05. 303 
3.0 Results   304 
Twenty volunteers (10 women, 10 men) gave written informed consent to participate in this 305 
trial. Following the baseline cold sensitivity test, 6 individuals (5 women, 1 man; age 25.8 ± 306 
4.2 y; height 1.71 ± 0.13 m; body mass 77.7 ± 17.7 kg) were withdrawn from the trial as they 307 
did not meet the skin temperature requirements to be classified as cold sensitive (House et 308 
al., 2015) (Figure 1). Fourteen individuals (Figure 1a) were randomised to start in either the 309 
nitrate supplementation arm or the placebo arm. One individual was subsequently 310 
withdrawn following randomisation (nitrate supplementation first, placebo second) due to 311 
use of mouthwash during the intervention period. Therefore, thirteen cold sensitive 312 
individuals completed the study (4 women, 9 men; age 34.5 ± 13.2 y; height 1.77 ± 0.07 m; 313 
body mass 85.0 ± 15.9 kg). Consistent with our previous findings (Shepherd et al., 2016) the 314 
beetroot juice was well tolerated and no adverse events (other than beeturia and 315 
discoloured stools) were reported, neither could the participants identify whether they had 316 
ingested the placebo or beetroot juice.  317 
 318 
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Figure 1A 320 
 321 
Figure 1B 322 
Figure 1. Participant flow through the trial (A) and average (SD) mean toe skin temperature 323 
during the Baseline cold sensitivity test in individuals with (n=13) and without cold 324 
sensitivity (n=6) (B). The dotted line represents the cut off skin temperature (Tsk) pre-325 
immersion (-2 minutes) and at 5 minutes of rewarming used for determining cold sensitivity.   326 
4.1 Plasma nitrate and nitrite concentrations 327 
There was a statistically significant rise in plasma nitrate (Baseline, 53.1 ± 29.4 µM; Placebo, 328 
50.5 ± 24.3 µM; nitrate supplementation, 756.8 ± 175.2 µM; F(2, 20) = 198.1, P < 0.001) and 329 
nitrite (Baseline, 73.7 ± 48.8 nM; Placebo, 73.5 ± 44.5 nM; nitrate supplementation, 501.5 ± 330 
245.8 nM; F(2, 20) = 33.6, P < 0.001) following nitrate supplementation when compared to 331 
Placebo and Baseline (Figure 2).  332 
 333 
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 334 
Figure 2. Mean (SD) and individual plasma nitrate (A) and nitrite (B) concentrations in the 335 
Baseline, Placebo and nitrate supplementation conditions (n=11). * P < 0.001 significantly 336 
different from Placebo and Baseline.  337 
 338 
4.2 Cold sensitivity test  339 
There was no effect of nitrate supplementation on skin blood flow in the Great toe (F (2, 24) = 340 
1.31, P = 0.289), or thumb (F (2, 24) = 0.42, P = 0.660; Figure 3) when compared to Placebo or 341 
Baseline.  342 
Skin blood flow was significantly different across time for the Great toe (F (2, 24) = 6.79, P = 343 
0.005) with a lower CVC observed at 5 min rewarming compared to pre-immersion (P = 344 
0.002; Figure 3A). Thumb skin blood flow also differed across time (F (2, 24) = 9.39, P = 0.001) 345 
with CVC being lower at 5 and 10 min of rewarming compared to pre-immersion (P = 0.025 346 
and P = 0.016 respectively; Figure 3C). 347 
There was no interaction between time and condition for skin blood flow in either the Great 348 
toe (F (4, 48) = 1.58, P = 0.195) or thumb (F (4, 48) = 0.62, P = 0.650) when nitrate 349 
supplementation was compared to Placebo and Baseline (Figure 3 and Table 1).  350 
There was no effect of nitrate supplementation on skin temperature of the Great toe (F (2, 24) 351 
= 0.70, P = 0.51), coldest toe (F (2, 24) = 0.81, P = 0.46), mean toe (F (2, 24) = 0.61, P = 0.55), or 352 
mean finger (pre immersion: X2 (2) = 2.57, P = 0.27, 5 minutes rewarming: X2 (2) = 2.63, P = 353 
0.27, or 10 minutes rewarming: X2 (2) = 2.47, P = 0.29).  354 
Skin temperature was significantly different across time for the Great toe (F (2, 24) = 14.8, P < 355 
0.001), coldest toe (F (2, 24) = 18.8, P < 0.001) and mean toe (F (2, 24) = 35.2, P < 0.001). Skin 356 
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temperature after 5 minutes of rewarming was colder than pre immersion (P = 0.028; P = 357 
0.001 P < 0.001 respectively) but had returned to pre-immersion temperatures after 10 358 
minutes (P = 0.318; P = 1.00; P = 1.00 respectively).  359 
There was no interaction between time and condition for skin temperature (Great toe: F (4, 360 
48) = 1.60, P = 0.19; coldest toe F (4, 48) = 1.81, P = 0.14; mean toe F (4, 48) = 0.81, P = 0.52) 361 
when nitrate supplementation was compared to Placebo and Baseline (Figure 3 and Table 362 
1). 363 
  364 
Figure 3. Skin blood flow and temperature during the cold sensitivity test of the foot and 365 
hand in the Baseline, Placebo and nitrate supplementation conditions. Mean (SD) cutaneous 366 
vascular conductance (CVC) in the Great toe (A) and thumb (B) and skin temperature (Tsk) in 367 
the Great toe (C) and thumb (D) are shown  (n = 13). 368 
 369 
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 372 
 373 
 374 
Table 1. Mean (SD) toe, coldest toe and mean finger skin temperature (Tsk) during the cold 375 
sensitivity test in the Baseline, Placebo and nitrate supplementation conditions (n = 13). 376 
 
          
     Rewarming  
 
    Pre immersion    5 minutes 10 minutes 
 
 Mean toe Tsk  
(°C) 
Baseline 29.4 ± 2.4 27.2 ± 2.3 29.6 ± 3.1 
 
 
Placebo 30.0 ± 3.2 28.7 ± 4.0 30.3 ± 3.9 
 
 
Nitrate supplementation 30.8 ± 3.5 29.0 ± 3.7 30.7 ± 3.4 
 
 
Coldest toe Tsk 
(°C) 
Baseline 28.2 ± 2.3 25.8 ± 1.9 28.5 ± 3.2 
 
 
Placebo 28.6 ± 3.3 27.6 ± 4.2 29.2 ± 4.2 
 
 
Nitrate supplementation 29.6 ± 3.6 28.1 ± 3.4 29.6 ± 3.4 
 
 
Mean finger Tsk 
(°C) 
Baseline 34.3 ± 1.7 33.1 ± 3.3 33.0 ± 3.0 
 
 
Placebo 34.6 ± 1.4 33.2 ± 3.1 33.6 ± 2.3 
 
 
Nitrate supplementation 34.5 ± 1.2 33.7 ± 1.8 34.0 ± 1.9 
 
 
  
     There were no differences in thermal sensation, thermal comfort or pain votes at any time 377 
point during the cold sensitivity test between conditions (Table 2). 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
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Table. 2. Thermal sensation, thermal comfort and pain in the foot and hand during the cold 387 
sensitivity test in the Baseline, Placebo and nitrate supplementation conditions (n=13). 388 
Average rewarm is the mean vote over the last 8 minutes of rewarming. 389 
 390 
4.3 Endothelial function 391 
Skin temperature during ACh iontophoresis was similar in both the Placebo and nitrate 392 
supplementation conditions (F (1, 11) = 0.30, P = 0.59; F (2, 22) = 0.54, P = 0.58; Table 3). As 393 
   
      
 
  
Condition  
Pre 
immersion 
During 
immersion 
Immediately 
after immersion 
Average rewarm 
 
Foot 
Thermal  
sensation  
Baseline 12.0 ± 2.2 4.9 ± 2.0 6.8 ± 2.7 10.0 ± 2.1 
 Placebo 12.2 ± 2.5 4.5 ± 1.5 6.3 ± 1.9 10.3 ± 1.9 
 Nitrate supplementation 13.3 ± 2.1 4.8 ± 1.9 6.5 ± 1.7 10.0 ± 1.4 
 
Thermal  
comfort 
Baseline 14.7 ± 1.9 9.5 ± 4.6 10.9 ± 4.4 13.1 ± 2.9 
 Placebo 13.4 ± 3.3 8.5 ± 3.0 10.9 ± 4.1 13.6 ± 3.1 
 Nitrate supplementation 13.4 ± 3.7 8.5 ± 3.8 9.9 ± 3.8 12.8 ± 3.0 
 
Pain 
Baseline 0.8 ± 1.0 0.4 ± 0.7 0.1 ± 0.3 0 ± 0 
 Placebo 0.5 ± 0.8 0.2 ± 0.6 0 ± 0 0 ± 0 
 Nitrate supplementation 0.9 ± 1.1 0.5 ± 0.8 0.1 ± 0.3 0 ± 0 
 
Hand 
Thermal  
sensation  
Baseline 12.7 ± 2.4  4.5 ± 1.6 6.3 ± 2.9 11.0 ± 2.7 
 Placebo 12.7 ± 2.0 4.4 ± 1.5 5.9 ± 1.9 11.0 ± 2.1 
 Nitrate supplementation 11.8 ± 2.0 5.2 ± 1.8 6.5 ± 2.4 11.5 ± 2.1 
 
Thermal  
comfort 
Baseline 14.6 ± 2.3 7.8 ± 3.8 8.5 ± 4.6 12.8 ± 2.3 
 Placebo 14.0 ± 3.2 8.7 ± 3.7 10.3 ± 4.0 13.5 ± 3.0 
 Nitrate supplementation 14.3 ± 3.1 7.9 ± 3.9 9.7 ± 4.1 13.2 ± 2.5 
 
Pain 
Baseline 0.9 ± 0.9 0.7 ± 0.9 0.1 ± 0.3 0 ± 0 
 Placebo 0.9 ± 1.2 0.3 ± 0.6 0.0 ± 0.8 0 ± 0 
 Nitrate supplementation 0.8 ± 1.1 0.5 ± 1.0 0.1 ± 0.3 0 ± 0 
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expected skin temperature was different between skin sites, with the foot being 3.6°C 394 
colder than the forearm and 2.6°C colder than the finger (F (2, 22) = 14.7, P < 0.001; Table 3). 395 
Average CVC prior to iontophoresis was similar between conditions, for the forearm (n=12, 396 
0.13 ± 0.08 flux.mmHg-1, P = 0.59), the finger (n=12, 0.66 ± 0.53 flux.mmHg-1, P = 0.60) and 397 
the foot (n = 13, 0.13 ± 0.09 flux.mmHg-1, P = 0.99). There was no effect of nitrate 398 
supplementation on the vasodilatory dose response to transdermal delivery of ACh in the 399 
forearm, finger or foot (Figure 4). Maximum skin blood flow (F (1, 11) = 0.01, P = 0.92) and 400 
AUC (F (1, 11) = 0.32, P = 0.59) were similar between Placebo and nitrate supplementation 401 
(Table 3) and no significant interactions were observed (maximum blood flow: F (2, 22) = 1.84, 402 
P = 0.18; AUC: F (2, 22) = 0.66, P = 0.53). No differences were seen in ED50 for the forearm (P = 403 
0.63), finger (P = 0.62) or foot (P = 0.30) between Placebo and nitrate supplementation 404 
(Table 3). However there was a difference between skin sites in the magnitude of the 405 
vasodilation to ACh (maximum skin blood flow: F (2, 22) = 19.7, P < 0.001; AUC: F (2, 22) = 14.3, P 406 
< 0.001; Figure 4 and Table 3).  407 
Table 3. Skin blood flow response to iontophoresis of ACh on the forearm, finger and foot in 408 
the Placebo and nitrate supplementation conditions. Data are given as mean ± SD for 409 
maximum CVC, area under the curve (AUC) and skin temperature (Tsk) and 95% confidence 410 
intervals are given for the ED50. 411 
            n Maximum (CVC) ED50 (µA) AUC Tsk (°C) 
 
Forearm 
Placebo 13 2.0 ± 1.0 75.9 to 118.8 9.6 ± 7.2 30.2 ± 1.2 
 Nitrate supplementation 13 2.3 ± 0.7 69.2 to 111.1 10.6 ± 5.3 30.1 ± 1.0 
 
Finger 
Placebo 12 3.3 ± 1.6 73.4 to 109.3 16.8 ± 11.1 29.5 ± 3.3 
 Nitrate supplementation 12 3.1 ± 1.5 67.3 to 102.8 15.1 ± 9.3 28.8 ± 3.3 
 
Foot 
Placebo 13 1.2 ± 0.8 105.0 to 147.6 4.7 ± 3.1 26.5 ± 1.9 
 Nitrate supplementation 13 1.0 ± 0.7  119.3 to 167.7 4.0 ± 2.8  26.6 ± 2.0 
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 412 
 413 
Figure 4. Cutaneous vascular conductance following iontophoresis of ACh on the forearm 414 
(A), finger (B) and foot (C) in the Placebo and nitrate supplementation conditions (n = 13 415 
participants), for finger CVC, n = 12 at cumulative current 400 and 600 µA).  416 
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There was no effect of nitrate supplementation on systolic blood pressure (Baseline, 123 ± 418 
12 mmHg, Placebo 121 ± 9 mmHg, nitrate supplementation 124 ± 13 mmHg; F (2, 22) = 0.87, P 419 
= 0.43), diastolic blood pressure (Baseline, 79 ± 10 mmHg, Placebo 74 ± 10 mmHg, nitrate 420 
supplementation 76 ± 11 mmHg; F (2, 22) = 2.81, P = 0.08) or mean arterial blood pressure 421 
(Baseline, 94 ± 11 mmHg, Placebo 90 ± 9 mmHg, nitrate supplementation 92 ± 11 mmHg; F 422 
(2, 22) = 2.29, P = 0.13) when compared to Placebo and Baseline.  423 
5.0 Discussion  424 
This is the first study to examine the effects of nitrate supplementation in the form of 425 
concentrated beetroot juice on extremity rewarming following a cold stimulus in individuals 426 
with cold sensitivity. Contrary to our hypotheses, acute nitrate supplementation did not 427 
alter extremity rewarming, endothelial function, blood pressure, pain or thermal comfort 428 
and sensation. This was despite a physiologically meaningful rise in plasma nitrite 429 
concentrations in the nitrate supplementation condition (Figure 2).  430 
Plasma nitrate and nitrite increased by 703.6 µM and 423.5 nM respectively following 431 
ingestion of beetroot juice containing 11.9 mmol of nitrate. This change from baseline in 432 
plasma nitrite concentration following nitrate supplementation is similar to that reported in 433 
other studies with similar supplementation regimes such as Webb et al. (2008) and Wylie et 434 
al. (2013) who report changes of 180 nM and 395 nM respectivley. We would note that due 435 
to our protocol design (venous blood samples were taken 1.5 hours post ingestion which is 436 
approximately 1 hour prior to peak plasma nitrate and nitrite concentrations (Wylie et al., 437 
2013)) we cannot preclude that nitrate and nitrate values maybe higher than what we have 438 
reported. This was done in order to enable the primary outcomes to be measured at the 439 
time of peak plasma nitrite concentration.  440 
There was no effect of nitrate supplementation on peripheral blood flow and skin 441 
temperature following exposure to a cold stimulus when compared to Placebo or Baseline 442 
(Figure 3 and Table 1). As a consequence nitrate supplementation did not improve thermal 443 
sensation, thermal comfort or reduce the associated pain with the cold stimulus when 444 
compared to Placebo or Baseline (Table 2). These findings were in contrast to our previous 445 
study which showed that organic nitrate (GTN spray) increased peripheral blood flow and 446 
skin temperature in drug naive individuals with cold sensitivity (Hope et al., 2014). The 447 
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disparity between the findings in our two studies is likely due to any combination of the 448 
differences between inorganic nitrate and organic nitrates, such as their pharmacokinetics, 449 
pharmacodynamics and bio-activation (Janero et al., 2004, Gilchrist et al., 2011, Omar et al., 450 
2012). Elucidating which of these differences were responsible for the lack of effect in 451 
peripheral blood flow in the current study requires further investigation. Irrespective of 452 
which of these differences are responsible for the lack of effect seen in this trial, it is difficult 453 
to compare organic and inorganic nitrates as NO• donors. For instance, 80-90% of GTN is 454 
metabolised by liver (Münzel et al., 2005) whereas, the oral microflora within the mouth are 455 
an essential component for the processing of inorganic nitrite production and subsequent 456 
NO• production (Duncan et al., 1995). These differences, among others are reviewed 457 
elsewhere by Münzel et al. (2005) and Omar et al. (2012).  458 
Elevations in reactive oxygen species have been shown in rat models of NFCI (Geng et al., 459 
2015) but have yet to be shown in individuals with cold sensitivity. However, individuals 460 
with cold sensitivity have significantly impaired microvasculature (see Figure 1 for 461 
comparison to the “normal” response) and therefore redox balance may be altered in 462 
favour of a pro-oxidant state (Bertuglia and Giusti, 2003). This would result in a reduced 463 
bioavailability of NO•, principally via uncoupling of endothelial nitric oxide synthase and 464 
reduction of tetrahydrobiopterin (Landmesser et al., 2003) which leads to an increase of 465 
superoxide’s and peroxynitrite. Further research is required to determine whether this sub-466 
clinical population have elevated levels of oxidative stress and whether chronic, rather than 467 
acute, beetroot juice supplementation would alter this redox balance thus restoring 468 
endothelial function. As individuals with cold sensitivity have cooler extremities they are 469 
likely to have diminished eNOS activity reducing NO• production (Kellogg et al., 2008). 470 
Longer term nitrate supplementation may alleviate these reductions in the NO• pool. 471 
Moreover, recent data have shown that nitrate supplementation may reduce sympathetic 472 
nervous activity (Notay et al., 2017) which may also be beneficial to individuals with cold 473 
sensitivity.   474 
Skin blood flow and temperature were lower in the toes than fingers during the cold 475 
sensitivity test (Figure 3; Table 1) and whilst all participants had cold sensitive feet, only one 476 
participant had cold sensitive hands. This is despite their self-reported cold exposures to 477 
involve the hands and feet to similar degrees. This supports a recent study which reported a 478 
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heterogeneous response of the hands and feet to a cold challenge (Norrbrand et al., 2017) 479 
and that the feet appear to be more susceptible to cold injury than the hands (DeGroot et 480 
al., 2003, Golden et al., 2013).  481 
There was no effect of nitrate supplementation on the skin blood flow response to 482 
transdermal delivery of ACh in the forearm, finger or foot when compared to Placebo. A 483 
previous study in patients with type 2 diabetes also showed no effect of nitrate 484 
supplementation on the response to ACh (Gilchrist et al. 2013). Other studies have reported 485 
nitrate supplementation resulted in an increase in CVC in the response to local (Keen et al., 486 
2014) and whole body (Levitt et al., 2015) heating in healthy individuals. The increase in CVC 487 
in these two studies was a function of a decreased MAP since raw flux data was not altered 488 
by nitrate supplementation, as in the current study. Differences in nitrate supplementation 489 
regime (a 3 day [~5 mmol/day] supplementation vs an acute dose 1.5 hours [~12 mmol] 490 
prior to testing) and the lack of a placebo in the other studies could explain the lack of effect 491 
of nitrate supplementation on MAP in the current study. It is possible that a longer 492 
supplementation period may augment ACh-induced vasodilation in the peripheral 493 
microvasculature. This study was designed to have peak plasma nitrite concentrations (~3 494 
hours post ingestion) during our primary outcome testing (cold sensitivity test) which means 495 
that the iontophoresis (endothelial function test) was likely to have been conducted at 496 
lower concentrations of plasma nitrite. We therefore, cannot exclude that, if the 497 
iontophoresis was conducted at peak plasma nitrite concentrations that nitrate 498 
supplementation could have been beneficial.   499 
There was no difference in systolic, diastolic or mean arterial BP following acute nitrate 500 
supplementation compared to Baseline or Placebo. Studies investigating short term nitrate 501 
supplementation and its effects on blood pressure in clinical populations with endothelial 502 
dysfunction have resulted in conflicting reports. For example, reductions in systolic blood 503 
pressure have been shown in individuals with chronic obstructive pulmonary disease (COPD) 504 
(Berry et al., 2014, Leong et al., 2015, Kerley et al., 2015) and hypertension (Kapil et al., 505 
2015) whilst in contrast, other studies have found no effect in individuals with COPD 506 
(Shepherd et al., 2015b, Curtis et al., 2014), type 2 diabetes (Gilchrist et al., 2013, Shepherd 507 
et al., 2015a) and heart failure (Zamani et al., 2015). Differences between these studies 508 
include, dosing strategies (~5 vs ~12 mmol), timing of the supplement (ranging from 1.5 509 
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hours to 4 days which may affect peak plasma nitrite concentrations (Leong et al., 2015)) 510 
and importantly, some studies did not include a true placebo (Berry et al., 2014, Kerley et 511 
al., 2015). Peak plasma nitrite and corresponding BP reductions typically occur at 2.5 to 4 512 
hours post nitrate ingestion (Wylie et al., 2013). We measured BP indices at 1.5 hours post 513 
ingestion for pragmatic reasons, therefore we are likely to have missed the peak in plasma 514 
nitrite concentration and cannot exclude that the lack of effect on BP maybe due to timing. 515 
Larger, well controlled studies are needed in clinical cohorts to elucidate if any clinically 516 
meaningful benefits of short term dietary nitrate supplementation exist as the evidence to 517 
date is equivocal.  518 
The main strength to this study is the rigorous experimental design (a double blind, placebo 519 
controlled, crossover, randomised control trial). As the current study examined acute 520 
supplementation, future research should explore the potential benefits of longer 521 
supplementation periods and examine if increasing the bioavailability of nitric oxide could 522 
improve endothelial function and microvascular responses to a cold challenge in individuals 523 
with impaired peripheral blood flow (e.g. non-freezing cold injury, Raynaud’s phenomenon 524 
and Scleroderma). A limitation to this study is that we did not measure change in redox 525 
balance. Antioxidants and polyphenols in the beetroot juice have the potential to alter NOx 526 
bioavailability. Given that the antioxidant and polyphenol content are the same for the 527 
nitrate enriched (nitrate supplementation) and depleted (Placebo) beetroot juices 528 
(Shepherd et al., 2015a) and that we showed no difference between baseline, placebo or 529 
nitrate supplementation conditions for any variable, it is unlikely that the acute 530 
consumption of beetroot and associated antioxidant / polyphenol content will have had any 531 
effect.  532 
6.0 Conclusion 533 
This is the first study to examine the effects of inorganic nitrate supplementation in the 534 
form of concentrated beetroot juice ingestion on rewarming following a cold stimulus in 535 
individuals with cold sensitivity. Despite a physiologically meaningful rise in plasma nitrite 536 
concentrations, acute nitrate supplementation did not alter extremity rewarming, 537 
endothelial function, blood pressure, pain or thermal comfort and sensation. Although we 538 
cannot preclude the possibility that a chronic nitrate supplementation regime could improve 539 
extremity rewarming and microvascular function in cold sensitive individuals, acute nitrate 540 
24 
 
supplementation does not appear to improve vascular function in this sub-clinical 541 
population following acute cold exposure.   542 
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